GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Antibiotice SA (BSE:ATB) » Definitions » Institutional Ownership

Antibiotice (BSE:ATB) Institutional Ownership : 0.11% (As of Jun. 10, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Antibiotice Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Antibiotice's institutional ownership is 0.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Antibiotice's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Antibiotice's Float Percentage Of Total Shares Outstanding is 0.00%.


Antibiotice Institutional Ownership Historical Data

The historical data trend for Antibiotice's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibiotice Institutional Ownership Chart

Antibiotice Historical Data

The historical data trend for Antibiotice can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11

Antibiotice Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Antibiotice (BSE:ATB) Business Description

Traded in Other Exchanges
N/A
Address
1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice Ord is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).

Antibiotice (BSE:ATB) Headlines

No Headlines